Fully automated solid-phase microextraction–fast gas chromatography–mass spectrometry method using a new ionic liquid column for high-throughput analysis of sarcosine and N-ethylglycine in human urine and urinary sediments

[Display omitted] ► Fully automated SPME–Fast GC–MS method for sarcosine and N-ethylglycine determination. ► Possibility of high-throughput analyses and point of care testing. ► Potential role of sarcosine as biomarker for prostate cancer detection. A fully automated, non invasive, rapid and high-th...

Full description

Saved in:
Bibliographic Details
Published inAnalytica chimica acta Vol. 707; no. 1; pp. 197 - 203
Main Authors Bianchi, F., Dugheri, S., Musci, M., Bonacchi, A., Salvadori, E., Arcangeli, G., Cupelli, V., Lanciotti, M., Masieri, L., Serni, S., Carini, M., Careri, M., Mangia, A.
Format Journal Article
LanguageEnglish
Published Amsterdam Elsevier B.V 30.11.2011
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:[Display omitted] ► Fully automated SPME–Fast GC–MS method for sarcosine and N-ethylglycine determination. ► Possibility of high-throughput analyses and point of care testing. ► Potential role of sarcosine as biomarker for prostate cancer detection. A fully automated, non invasive, rapid and high-throughput method for the direct determination of sarcosine and N-ethylglycine in urine and urinary sediments using hexyl chloroformate derivatization followed by direct immersion solid-phase micro extraction and fast gas chromatography–mass spectrometric analysis was developed and validated. The use of a new ionic liquid narrow bore column, as well as the automation and miniaturization of the preparation procedure by a customized configuration of the utilized XYZ robotic system, allowed a friendly use of the GC apparatus achieving a quantitation limit of 0.06 μg L −1 for sarcosine, good repeatability with CV always lower than 7% and reduced analysis times useful for point-of-care testing. The method was then applied for the analysis of 56 samples of urine and urinary sediments in healthy subjects, in those with benign prostatic hypertrophy and in patients with clinically localized prostate cancer. The results obtained showed that the medians of sarcosine/creatinine in urine were 103, 137 and 267 μg g −1 respectively, thus assessing the potential use of sarcosine as urinary biomarker for prostate cancer detection. The highest values of sensitivity (79%) and specificity (87%) were obtained in correspondence of a cut-off value of 179 μg sarcosine (g creatinine) −1, thus by using this cut-off threshold, sarcosine was significantly associated with the presence of cancer ( p < 0.0001). Finally, ROC analyses proved that the discrimination between clinically localized prostate cancer and patients without evidence of tumor is significantly correlated with sarcosine.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0003-2670
1873-4324
1873-4324
DOI:10.1016/j.aca.2011.09.015